Mark L. Pacala - 26 Mar 2025 Form 4 Insider Report for Oncology Institute, Inc. (TOI)

Role
Director
Signature
/s/ Mark Hueppelsheuser, Attorney-in-Fact for Mark L. Pacala
Issuer symbol
TOI
Transactions as of
26 Mar 2025
Net transactions value
+$99,624
Form type
4
Filing time
28 Mar 2025, 17:41:49 UTC
Previous filing
25 Nov 2024
Next filing
20 Nov 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TOI Common Stock Purchase $94,338 +90,562 +67% $1.04* 224,971 26 Mar 2025 By LLC F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TOI Common Warrant Purchase $5,285 +42,281 $0.1250 42,281 26 Mar 2025 Common Stock 42,281 $1.20 By LLC F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
F2 Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250.
F3 Securities were purchased by Pacala Enterprises, LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein.
F4 The holder may not exercise any portion of a Common Warrant to the extent that the holder would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Securities Exchange Act of 1934, as amended.